Avoiding false negative results in specificity analysis of protein-protein interactions

Journal of Molecular Recognition

Volumn 24, Issue 1, 2011, Pages 81-89

  Björkelund, Hanna ^a,b   Gedda, Lars ^a   Andersson, Karl ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Ridgeview Instruments AB   (Sweden)

Author keywords

affinity; competition assay; kinetics; specificity

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND;

ARTICLE; BIOCHEMISTRY; BIOLOGICAL MODEL; ENZYME SPECIFICITY; HUMAN; ISOTOPE LABELING; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE;

BIOCHEMISTRY; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HUMANS; ISOTOPE LABELING; LIGANDS; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; SUBSTRATE SPECIFICITY;

EID: 78650909454     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1026     Document Type: Article

References (11)

1. Björke H, Andersson K, 2006. Automated, high-resolution cellular retention and uptake studies in vitro. Appl. Radiat. Isot. 64 (8): 901-905. DOI: 10.1016/j.apradiso.2006.03.002 (Pubitemid 43817538)
2. Hunter WM, Greenwood FC, 1962. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 194: 495-496. DOI: 10.1038/194495a0
3. Jones RB, Gordus A, Krall JA, MacBeath G, 2006. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 438: 168-174. DOI: 10.1038/nature04177 (Pubitemid 43083134)
4. Karlsson R, Kullman-Magnusson M, Hämäläinen MD, Remaeus A, Andersson K, Borg P, Gyzander E, Deinum J, 2000. Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. Anal Biochem. 28 (1): 1-13. DOI: 10.1006/abio.1999.4406 (Pubitemid 30069062)
5. Khomyakova E, Livshits MA, Steinhauser MC, Dauphinot L, Cohen-Kaminsky S, Rossier J, Soussaline F, Potier MC, 2008. On-chip hybridization kinetics for optimization of gene expression experiments. BioTechniques 44: 109-117. DOI: 10.2144/000112622 (Pubitemid 351251670)
6. Nature publishing group. 2006. Protein interactions à la carte. Nat. Methods 3 (12): 957-958. DOI: 10.1038/nmeth1206-957 (Pubitemid 44782684)
7. Önell A, Andersson K, 2005. Kinetic determinations of molecular interactions using Biacore-minimum data requirements for efficient experimental design. J. Mol. Recognit. 18: 307-317. DOI: 10.1002/jmr.745 (Pubitemid 41059727)
8. Rich RL, Myszka DG, 2008. Survey of the year 2007 commercial optical biosensor literature. J. Mol. Recognit. 21: 355-400. DOI: 10.1002/jmr.928
9. Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, Tolmachev V, Carlsson J, 2003b. Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. J. Nucl. Med. Mol. Imaging 30 (10): 1348-1356. DOI: 10.1007/s00259-003-1308-9 (Pubitemid 37247951)
10. Sundberg A, Orlova A, Bruskin A, Gedda L, Carlsson J, Blomquist E, Lundqvist H, Tolmachev V, 2003a. [(111)In]Bz-DTPA-hEGF: preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. Cancer Biother. Radiopharm. 18 (4): 643-654. DOI: 10.1016/j.ijrobp.2006.07.1369
11. Zeder-Lutz G, Benito A, Van Regenmortel MH, 1999. Active concentration measurements of recombinant biomolecules using biosensor technology. J. Mol. Recognit. 12 (5): 300-309. DOI: 0.1021/bi020099h